GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.3464

Change

-0.01 (-3.24)%

Market Cap

N/A

Volume

0.16M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-6.71 (-1.47%)

USD 117.52B
REGN Regeneron Pharmaceuticals Inc

-16.77 (-1.66%)

USD 111.65B
ALNY Alnylam Pharmaceuticals Inc

-1.22 (-0.46%)

USD 34.40B
ARGX argenx NV ADR

-7.16 (-1.35%)

USD 32.98B
BGNE BeiGene Ltd

-3.02 (-1.23%)

USD 27.28B
MRNA Moderna Inc

-1.48 (-2.46%)

USD 25.27B
RPRX Royalty Pharma Plc

-0.18 (-0.65%)

USD 16.47B
UTHR United Therapeutics Corporatio..

-6.08 (-1.71%)

USD 15.95B
SMMT Summit Therapeutics PLC

-0.17 (-0.89%)

USD 14.03B
PCVX Vaxcyte Inc

-2.83 (-2.54%)

USD 13.78B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

-0.04 (-1.06%)

N/A
UKRE:LSE iShares MSCI Target UK Re.. 2.53 % 0.00 %

-2.00 (-1.06%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.03% 36% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.03% 36% F 35% F
Trailing 12 Months  
Capital Gain -77.79% 6% D- 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.79% 6% D- 5% F
Trailing 5 Years  
Capital Gain -99.29% 1% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.29% 1% F N/A F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector